DOCSLIB.ORG

En Este Número

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
En Este Número Boletín Científico No. 16 (2-15 junio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de la información pu- investigadores y especialistas dedicados a blicada por la OMS sobre los la vacunología y temas afines, con el ob- candidatos vacunales contra la jetivo de serle útil. Usted puede realizar COVID-19 en desarrollo a nivel sugerencias sobre los contenidos y de es- mundial. ta forma crear una retroalimentación Artículos científicos más recien- que nos permita acercarnos más a sus tes de Medline sobre vacunas. necesidades de información. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Boletín VacCiencia Resumen de la información publicada por la OMS sobre los candidatos vacunales contra la COVID-19 en desarrollo a nivel mundial Última actualización por la OMS: 15 de junio de 2021. Fuente de información utilizada: 102 candidatos vacunales en evaluación clínica y 185 en evaluación preclínica. Candidatos vacunales en evaluación clínica por plataforma 2| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Boletín VacCiencia Candidatos vacunales más avanzados a nivel global Desarrollador de la vacuna/fabricante/país Plataforma de la vacuna Fase Sinovac/China Virus Inactivado 4 Wuhan Institute of Biological Products/Sinopharm/China Virus Inactivado 3 Beijing Institute of Biological Products/Sinopharm/China Virus Inactivado 3 University of Oxford/AstraZeneca/Reino Unido Vector viral no replicativo 4 CanSino Biological Inc./Beijing Institute Biotechnology/China Vector viral no replicativo 4 Gamaleya Research Institute/Rusia Vector viral no replicativo 3 Janssen Pharmaceutical Companies/Estados Unidos Vector viral no replicativo 3 Novavax/Estados Unidos Subunidad proteica 3 Moderna/NIAID/Estados Unidos ARN 4 Pfizer/BioNTech Fosun Pharma/Estados Unidos ARN 4 Anhui Zhifei Longcom Biopharmac./Inst. Microbiology, Chinese Academy Sciences Subunidad proteica 3 CureVac AG/Alemania ARN 3 Institute of Medical Biology/Chinese Academy of Medical Sciences Virus inactivado 3 Research Institute for Biological Safety Problems, Kazakhstan Virus inactivado 3 Zydus Cadila Healthcare Ltd./India ADN 3 Bharat Biotech/India Virus Inactivado 3 Sanofi Pasteur + GSK/Francia/Gran Bretaña Subunidad proteica 3 Shenzhen Kangtai Biological Products Co., Ltd./ China Virus Inactivado 3 Instituto Finlay de Vacunas/Cuba Subunidad proteica 3 Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"/Rusia Subunidad proteica 3 Academy Military Science (AMS) Walvax Biotechnology, Suzhou Abogen Bioscience/China ARN 3 Center for Genetic Engineering and Biotechnology (CIGB)/Cuba Subunidad proteica 3 Valneva, National Institute for Health Research, Reino Unido Virus inactivo 3 Candidatos vacunales mucosales en evaluación clínica Desarrollador de la vacuna/fabricante/país Plataforma de la vacuna Vía de administración Fase University of Oxford/Reino Unido Vector viral no replicativo Intranasal 1 Vaxart/Estados Unidos Vector viral no replicativo Oral 1 Univ. Hong Kong, Xiamen Univ./Beiging Wantai Biol. Pharm./ China Vector viral replicativo Intranasal 2 Symvivo/Canadá ADN Oral 1 ImmunityBio, Inc./Estados Unidos Vector viral no replicativo Oral or IM 1/2 Codagenix/Serum Institute of India Virus vivo atenuado Intranasal 1 Center for Genetic Engineering and Biotechnology (CIGB)/ Cuba Subunidad proteica Intranasal 1/2 Altimmune, Inc./Estados Unidos Vector viral no replicativo Intranasal 1 Razi Vaccine and Serum Research Institute/India Subunidad proteica Intranasal 2 Bharat Biotech International Limited/India Vector viral no replicativo Intranasal 1 Meissa Vaccines, Inc./Estados Unidos Virus vivo atenuado Intranasal 1 Laboratorio Avi-Mex/México Virus inactivado IM o IN 1 VaxForm/Estados Unidos Subunidad proteica Oral 1 3| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Boletín VacCiencia Noticias en la Web Cuba espera una eficacia "mucho mayor de 50%" en las vacunas que desarrolla 2 jun. Las autoridades sanitarias cubanas confían en que los dos candidatos vacunales contra la covid-19 más avanzados que se desarrollan en la isla, ya en tercera y última etapa de ensayos clínicos, superen el 50 % de eficacia a partir de los resultados obtenidos en la segunda etapa de pruebas. "Más del 90% de los voluntarios de fase II tuvieron una respuesta de títulos de anticuerpos cuatro veces por encima de los niveles basales (...). A partir de estos datos esperamos una eficacia mucho mayor al 50 %", dijo este miércoles en una rueda de prensa Eduardo Martínez, presidente del grupo estatal de empresas de la industria biofarmacéutica, BioCubaFarma. El nivel de eficacia que la Organización Mundial de la Salud (OMS) ha establecido para que las vacunas contra el SarS-CoV-2 sean consideradas como tales es del 50 %. Los dos inmunógenos experimentales, Soberana 02 y Abdala, se encuentran en la recta final de ensayos. En mayo concluyó la aplicación de dosis a los voluntarios -más de 90.000 entre ambos fármacos- que participan en la tercera fase, que es la que determina la eficacia de la potencial vacuna. EL RETO DE LAS VARIANTES "En junio debemos conocer los primeros resultados de eficacia", avanzó Martínez en presencia de los máximos responsables de los dos organismos que desarrollan estos candidatos: el Instituto Finlay de Vacunas (IFV) y el Centro de Ingeniería Genética y Biotecnología (CIGB). El responsable de Biocubafarma consideró que la eficacia de las potenciales vacunas cubanas se está evaluando en un "contexto retador" por la continua aparición de nuevas variantes. Aseguró, no obstante, que esperan una "buena eficacia" incluso en los escenarios en que se mueve el virus, en referencia a las variantes que circulan en Cuba en la actualidad, entre las que prevalece la sudafricana. Respecto a la seguridad, ya probada durante la segunda fase de ensayos, los científicos reiteraron que se trata de fármacos muy seguros que no han mostrado ningún efecto adverso "no esperado", con efectos secundarios leves en un 95 % de los casos y moderados en el 5 % restante. JUNIO, MES CLAVE Soberana 02 y Abdala, ambas de aplicación intramuscular, son vacunas de subunidad basadas en el sitio de unión al receptor (RBD) de la proteína S del virus. En el caso de la primera, el antígeno del virus se conjuga con el toxoide tetánico para estimular la respuesta del sistema inmune. A partir de todo lo anterior, las instituciones científicas confían en lograr en junio la autorización de uso de emergencia por parte de las autoridades sanitarias del país, lo que daría paso a la vacunación masiva en la isla, que atraviesa el peor momento de la pandemia y no ha importado vacunas ni forma parte del mecanismo Covax. EL CIGB y el IFV también esperan iniciar este mes los ensayos clínicos para el uso pediátrico de las dos fórmulas. Tanto Soberana 02 como Abdala ya están siendo administradas a cientos de miles de personas en Cuba - especialmente en La Habana y la zona oriental de la isla- en paralelo a los ensayos clínicos tradicionales, bajo la figura de estudios de intervención sanitaria. Hasta ahora, más de un millón de personas ha recibido al menos una dosis de las tres de las que constan los esquemas de inmunización de ambos candidatos. INTERÉS INTERNACIONAL Respecto a las perspectivas de comercialización internacional, la vicepresidenta de Biocubafarma, Mayra 4| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Boletín VacCiencia Mauri, comentó que Cuba se encuentra en conversaciones con más de 30 países, "tanto con gobiernos como con empresas privadas". Precisó que una vez que el órgano regulador cubano conceda la autorización de uso de emergencia para los candidatos vacunales, comenzará el proceso para obtenerlo con las autoridades reguladoras de los países interesados. "No vamos a firmar contratos que no podamos cumplir", subrayó. Entre los países que se han interesado por las vacunas figuran Argentina -con cuyo Gobierno se firmó un acuerdo la semana pasada-, México, Venezuela, Bolivia e Irán (donde hay en marcha una tercera fase de ensayos con Soberana 02). Los científicos cubanos insistieron hoy en las dificultades que enfrentan debido al embargo de Estados Unidos, endurecido en los últimos años con consecuencias que también repercuten en la investigación de las vacunas. Una "discriminación" que también se hace extensiva a la publicación de artículos en revistas internacionales, denunció el director del IFV, Vicente Vérez, quien resaltó lo complicado que es lograr su aparición en publicaciones especializadas del sector. "Hay un menosprecio de las publicaciones internacionales a partir del país del que vienen (los artículos) (...). Pero estamos publicando, no estamos escondiendo resultados, añadió. Fuente: swissinfo. Disponible en https://cutt.ly/9nHaCd8 Cuba thanks Bolivia for acknowledging COVID-19 vaccine candidates Jun 2. Cuban President Miguel Diaz-Canel on Wednesday thanked his Bolivian counterpart, Luis Arce, for acknowledging the progress of the health intervention in Cuba with its own COVID-19 vaccine candidates. On his official Twitter account, the president said that the country is making history with the immunization process in risk groups and territories with Phase 3 vaccine candidates Soberana 02 and Abdala, which will also benefit Latin America. On Tuesday, also on this platform, Arce greeted Diaz-Canel and highlighted the vaccination
Load more

Recommended publications
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Storage Best Practices for Frozen Vaccines-Fahrenheit
    Storage Best Practices for Frozen Vaccines–Fahrenheit (F) 1 Unpack vaccines immediately 1. Place the vaccines in trays or containers for proper air flow. 2. Put vaccines that are first to expire in front. HEP A - VFC 3. Keep vaccines in original boxes with lids closed to prevent exposure to light. 4. Separate and label vaccines by type and public (VFC) or private. 2 Thermostat should be at the factory-set or midpoint temperature setting Frozen Vaccines Too Cold! Within Range Too Warm! Take Action! Take Action! Report out-of-range temperatures immediately! -70° F -65° F -60° F -50° F -45° F -40° F -35° F 10° F 15° F -58° F 5° F 3 Use vaccine storage best practices Freezer Only DO temp range ✓ Do make sure the freezer door is closed! -58° F to 5° F ✓ Do use water bottles to help maintain consistent temperature. ✓ Do leave 2 to 3 inches between vaccine containers and freezer walls. don’t block vents ✓ Do post “Do Not Unplug” signs on freezer and by electrical outlet. do not unplug DON’T Don’t use dormitory-style refrigerator/freezer. Don’t use combo refrigerator/freezer unit. Don’t put food in freezer. Don’t store vaccines on shelves in freezer door. CS243541-D Revision December 2020 Distributed by Visit www.cdc.gov/vaccines/SandH or contact your state health department for more information. Test Your Knowledge 1 Which of the following units is the best for storing frozen vaccines? Freezer Freezer Freezer Freezer A. Full-size B. Full-size C. Stand-alone D.
    [Show full text]
  • CDC Vaccine Storage and Handling Guide
    Table of Contents General Information Vaccine Storage and Handling Best Practices 5 Selected Biologicals Diphtheria Toxoid-, Tetanus Toxoid- and acellular Pertussis-Containing Vaccines DTaP: DAPTACEL, Infanrix, Tripedia 11 DTaP-IPV: KINRIX 11 DTaP-HepB-IPV: Pediarix 11 DTaP-IPV/Hib: Pentacel 11 Haemophilus influenzae type b-Containing Vaccines Hib: ActHIB, Hiberix, PedvaxHIB 15 Hib-HepB: Comvax 15 DTaP-IPV/Hib: Pentacel 11 Hepatitis-Containing Vaccines HepA: Havrix, VAQTA 19 HepB: Engerix-B, Recombivax HB 19 HepA-HepB: Twinrix 19 Vaccine Storage and Handling Guide and Storage Vaccine National Center for Immunization and Respiratory Disease DTaP-HepB-IPV: Pediarix 11 Hib-HepB: Comvax 15 Human Papillomavirus Vaccines HPV2: Cervarix 23 HPV4: Gardasil 23 Vaccine Storage and Handling Guide —————————————————————————————— Page 2 Table of Contents Influenza Vaccines LAIV: FluMist 27 TIV: Afluria, Fluarix, FluLaval, Fluvirin, Fluzone, Fluzone High-Dose, Fluzone Intradermal 29 Measles-, Mumps- and Rubella-Containing Vaccine MMR: M-M-RII 33 MMRV: ProQuad 69 Meningococcal Vaccines MCV4: Menactra, Menveo 37 MPSV4: Menomune 41 Pneumococcal Vaccines PCV13: Prevnar 13 45 PPSV23: Pneumovax 23 45 Poliovirus-Containing Vaccine IPV: IPOL 49 DTaP-HepB-IPV: Pediarix 11 DTaP-IPV: KINRIX 11 Vaccine Storage and Handling Guide and Storage Vaccine National Center for Immunization and Respiratory Disease DTaP-IPV/Hib: Pentacel 11 Rotavirus Vaccines RV1: ROTARIX 53 RV5: RotaTeq 53 Tetanus Toxoid Vaccine TT: Tetanus Toxoid 57 Vaccine Storage and Handling Guide ——————————————————————————————
    [Show full text]
  • The Falling Netanyahu Takes Down a Cantankerous Political Class
    WWW.TEHRANTIMES.COM I N T E R N A T I O N A L D A I L Y 8 Pages Price 50,000 Rials 1.00 EURO 4.00 AED 43rd year No.13954 Saturday MAY 29, 2021 Khordad 8, 1400 Shawwal 17, 1442 Elections is Brighton’s Alireza Steel ingot export Germany recognizes competition to Jahanbakhsh to decide rises 135% in colonial-era massacres in serve people Page 2 on his future Page 3 a month on year Page 4 Namibia as genocide Page 5 Unity is the secret behind the Resistance’s victories: Amir-Abdollahian TEHRAN - Hossein Amir-Abdollahian, the resistance and steadfastness victory could special aide to the speaker of the Iranian be achieved. This victory sent an important Parliament on international affairs, has re- message that the Zionist enemy only under- flected on the secret behind the recent victory stands the language of force and resistance,” of the Palestinian resistance against Israel. he told the Lebanese Al-Ahed News. Amir-Abdollahian said the 2006 victo- The Iranian diplomat added, “This ry of the Lebanese resistance movement victory and other victories achieved by against Israel raised faith in the resistance the resistance, especially the victory of and sent a message that Israel understands July 2006, were achieved in light of the only the language of power. unity of the Lebanese people and the gold- “The flight of the Zionist entity from en equation in Lebanon – the army, the southern Lebanon raised faith in the resist- people, and the resistance. Crabs in ance among the Lebanese, and that through Continued on page 3 Tehran, Moscow confer on joint investment in agricultural sector TEHRAN – Iranian Agriculture Minis- investment in various agricultural fields.
    [Show full text]
  • Outdoor, Online Activities Mark National Sport
    BUSINESS | Page 1 SPORT | Page 1 Envoy affi rms US Bayern Munich fi rms’ support for eye sixth title aft er 2030 Qatar Vision, reaching Club jobs creation World Cup fi nal published in QATAR since 1978 WEDNESDAY Vol. XXXXI No. 11820 February 10, 2021 Jumada II 28, 1442 AH GULF TIMES www. gulf-times.com 2 Riyals His Highness the Amir Sheikh Tamim bin Hamad al-Thani celebrated Qatar’s National Sport Day at Al Bidda Park yesterday. His Highness the Amir also wished everyone an enjoyable day through a tweet, whose unoff icial translation is as follows: “On our Sport Day during this exceptional year that all countries of the world are experiencing, exercise remains an indispensable healthy and social behaviour; wishing everyone an enjoyable day.” Doha Plan of Action Defence minister opens world’s to uplift poor nations Outdoor, online activities largest calisthenics park The Doha Plan of Action will be a starting point for transforming the lives of millions of people living in the most vulnerable countries, mark National Sport Day and putting the least developed countries on the path towards sustainable and comprehensive t was a National Sport Day (NSD) stances, in addition to being a highly development, HE the Permanent 2021 with a diff erence as people eff ective activity in terms of fi tness Representative of Qatar to the Iaround Qatar celebrated the occa- and well-being. United Nations Ambassador Sheikha sion yesterday by observing Covid-19 Others were seen running, jog- Alya Ahmed bin Saif al-Thani, has precautionary and preventive meas- ging, roller skating or simply walking, said.
    [Show full text]
  • Asia COVID-19 & Vaccine Tracker
    9 July 2021 Free to View Asia COVID-19 & Vaccine Tracker Economics - Asia Tougher restrictions As COVID-19 cases continue to surge across Asia, more Yun Liu authorities have re-imposed restrictions or even lockdowns Economist The Hongkong and Shanghai Banking Corporation Limited But this has increased the urgency to ramp up vaccine Frederic Neumann procurement and roll-out in the region Co-Head of Asian Economics Research The Hongkong and Shanghai Banking Corporation Limited Some economies have started pilot programmes to revive tourism, but a full re-opening may take a long time Maitreyi Das Associate Bangalore Déjà vu No end in sight just yet. The Delta variant is causing daily new COVID-19 cases to surge to new record highs across Asia, prompting more governments to re-impose tougher restrictions. This is particularly evident in ASEAN, where cases in Indonesia and Vietnam have been rising sharply. The former has extended its tightening measures throughout the country until 20 July, while the latter will impose a strict lockdown in Ho Chi Minh City (HCMC) from 9 July for 15 days. Meanwhile, just two weeks before the Tokyo Olympics, Japan is set to declare its fourth state of emergency in Tokyo from 12 July to 20 August, raising the possibility of no spectators attending the games. Meanwhile, Singapore is the only country that has decided to ease its social restrictions from 12 July, as new cases remain low. Urgency on vaccination The recent outbreaks in the region has alerted the authorities that the key to exiting the pandemic is to accelerate vaccine procurement and roll-out.
    [Show full text]
  • COVID-19 Vaccine Storage & Handling
    COVID-19 Vaccine Storage & Handling Brooke Zeringue, Adrienne Whitney, & Robert Starszak Louisiana Department of Health Office of Public Health Immunization Program • Everyone (16 years and older) can be vaccinated. Louisiana Order COVID-19 vaccine in LINKS. Second COVID-19 doses are not automatically ordered. You must Vaccination order every dose you need. Guidelines All vaccine doses administered must be entered into LINKS within 24 hours and inputted as administered, NOT historical. COVID-19 Vaccine Delivery Storage & Handling for Moderna COVID-19 Vaccine: Direct from McKesson Vaccine will arrive frozen Larger quantities Thermal Shipper Storage & Handling for Pfizer- BioNTech COVID-19 Vaccine: Direct from Shipped in thermal shipping container Pfizer Vaccine arrives frozen Larger quantities Storage & Handling for Moderna COVID-19 Vaccine: Morris & Dickson Vaccine will arrive thawed Smaller Quantities Johnson & Johnson (Janssen) COVID-19 Vaccine Vaccine Type: • Viral Vector Vaccine Age indication: Overview of • 18 years or older. the Johnson & Dose & Route: Johnson • 0.5 mL; intramuscular COVID-19 Schedule: Vaccine • Single dose Dose Preparation: • 5 doses per vial Johnson & Johnson | STORING VACCINE VIALS Refrigerator 2°C to 8°C (36°F to 46°F) • Store up to the expiration date • DO NOT store frozen • Protect from light • You can find the expiration date at vaxcheck.jnj Johnson & Johnson | ADMINISTERING • Keep refrigerated until thawed (if arrived frozen). Refrigerator • PUNCTURED VIALS: Viable up to 6 hours 2°C to 8°C (36°F to 46°F) • If arrived frozen and needed immediately, thaw for Room 1 to 2 hours. • UNPUNCTURED VIALS: Viable up to 12 hours kept Temperature at 9°C to 25°C (47°F to 77°F) • PUNCTURED VIALS: Viable up to 2 hours Up to 25°C (Up to 77°F) Johnson & Johnson | ADMINISTERING Visually inspect the Before withdrawing each Johnson & Johnson COVID- dose of vaccine, carefully 19 vaccine vials for other mix the contents by Each dose must contain 0.5 particulate matter and/or swirling gently in an upright mL of vaccine.
    [Show full text]
  • Bibi's Big Mistake: Fall of Fake Regime?
    WWW.TEHRANTIMES.COM I N T E R N A T I O N A L D A I L Y 8 Pages Price 50,000 Rials 1.00 EURO 4.00 AED 43rd year No.13941 Wednesday MAY 12, 2021 Ordibehesht 22, 1400 Ramadan 29, 1442 Iran: Tehran-Riyadh Daei, Hejazi the best Blood donation dialogue conducted by Iranian players of up 27% during Felicitation special envoys Page 2 century: IFFHS Page 3 Qadr nights Page 7 on Eid-al Fitr Iran rejects Pentagon’s claim, denounces U.S. ‘unprofessional’ behavior in Hormuz Bibi’s big mistake: Fall TEHRAN - The Islamic Revolutionary committing “provocative, gratuitous and Guards Corps Navy has reacted to a claim unprofessional behaviors such as flying heli- by the Pentagon that the IRGC speed- copters, firing flares and aimless shooting.” boats unprofessionally came close to an The statement said the IRGC boats See page 3 American vessel. maintained a legal distance from the The IRGC Navy said in a statement on American vessels in accordance with of fake regime? Tuesday that IRGC boats did not act unpro- international maritime regulations and fessionally and while they were conducting warned them against “dangerous and a regular and conventional operation, they unprofessional behavior.” encountered seven American Navy vessels Continued on page 3 Iranian COVID-19 Electricity projects worth over $320m vaccine enters large- put into operation TEHRAN – Iranian Energy Minister projects, as well as installing new PV sys- Reza Ardakanian inaugurated major tems for nomadic households. scale production phase electricity projects worth 13.45 trillion The national electricity network’s rials (about $320.2 million) across the new dispatching center which has been country on Tuesday, in the sixth week of completed with 11.44 trillion rials (about the ministry’s A-B-Iran program in the $272.3 million) of investment is using current Iranian calendar year (started on world’s latest technologies in Energy March 21).
    [Show full text]
  • En Este Número
    Boletín Científico No. 18 (1-10 julio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de candidatos vacu- investigadores y especialistas dedicados a nales contra la COVID-19 ba- la vacunología y temas afines, con el ob- sadas en la plataforma de sub- jetivo de serle útil. Usted puede realizar unidad proteica en desarrollo a sugerencias sobre los contenidos y de es- nivel mundial. (segunda parte) ta forma crear una retroalimentación Artículos científicos más que nos permita acercarnos más a sus recientes de Medline sobre necesidades de información. vacunas. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Resumen de vacunas contra la COVID-19 basadas en la plataforma de subunidad proteica en desarrollo a nivel mundial (segunda parte) Las vacunas de subunidades antigénicas son aquellas en las que solamente se utilizan los fragmentos específicos (llamados «subunidades antigénicas») del virus o la bacteria que es indispensable que el sistema inmunitario reconozca. Las subunidades antigénicas suelen ser proteínas o hidratos de carbono. La mayoría de las vacunas que figuran en los calendarios de vacunación infantil son de este tipo y protegen a las personas de enfermedades como la tos ferina, el tétanos, la difteria y la meningitis meningocócica. Este tipo de vacunas solo incluye las partes del microorganismo que mejor estimulan al sistema inmunitario. En el caso de las desarrolladas contra la COVID-19 contienen generalmente, la proteína S o fragmentos de la misma como el Dominio de Unión al Receptor (RBD, por sus siglas en inglés).
    [Show full text]
  • INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student
    INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student We have provided a list of Selected Countries to help you find the COVID-19 vaccine you may have already received. Please see the “WHO” list below to find your COVID-19 vaccine, and if it has been APPROVED. And please upload your record following these directions: https://youtu.be/wvBGeRqIMHc If you see that your vaccine HAS NOT yet been approved by “WHO”, you may be required to receive an approved COVID-19 vaccine and upload those records to meet UC campus policy and requirements. Many US Airports are now providing COVID-19 vaccine on-site. Here is a list of several California Airports that you may arriving where you may receive a vaccine IMMEDIATELY upon your entry into the U.S. LAX – Los Angeles https://www.flylax.com/TravelSafely SNA – Orange County https://hoagurgentcare.com/airport/ SFO – San Francisco https://www.flysfo.com/travel-well/vaccination-site-sfo If you have any additional questions or concerns, please call (949)824-2300 for support. THANK YOU for helping to ensure UCI continues to be a SAFE and HEALTHY Campus! Dr Chang INDIA SOUTH KOREA TAIWAN INDONESIA VIETNAM JAPAN Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Oxford–AstraZeneca Oxford-AstraZeneca Sinovac Sputnik V Pfizer–BioNTech Covishield Pfizer–BioNTech Oxford–AstraZeneca Oxford–AstraZeneca Sinopharm Janssen Sinopharm Moderna Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Moderna Covaxin Novavax Moderna Johnson & Johnson Oxford–AstraZeneca Sputnik V Novavax Nanocovax Johnson & Johnson Sputnik V COVIVAC Sputnik V CanSino Vabiotech MVC-COV1901 ZyCoV-D Corbevax Covovax .
    [Show full text]
  • 31St May-6Th June Weekly Compilation
    31st May -6th June Weekly Compilation (The Hindu+ Indian Express + PIB + Other World Wide News) PM CARES FOR CHILDREN SCHEME (Source: The HINDU) Why in News: The Prime Minister has announced a special PM-CARES for Children scheme. The scheme includes a comprehensive financial aid package for children orphaned during the pandemic. PM-CARES for Children Scheme The PM-CARES for Children Scheme will support children who have lost both parents or surviving parent or legal guardian/adoptive parents due to Covid-19. Features of the PM-CARES for Children Scheme Fixed Deposit in the name of the child . PM CARES will create a corpus of Rs 10 lakh for each child when s/he reaches 18 years of age. This corpus will be used to give monthly financial support from 18 years of age for the next five years. On reaching the age of 23 years, he or she will get the corpus amount as one lump sum for personal and professional use. School Education: For children under 10 years . The child will be given admission to the nearest Kendriya Vidyalaya or in a private school as a day scholar. If the child is admitted to a private school, the fees as per the Right to Education(RTE) norms will be given from the PM CARES. School Education: for children between 11-18 years: . The child will be given admission to any Central Government residential school such as Sainik School, Navodaya Vidyalaya etc. In case the child is to be continued under the care of Guardian. Then s/he will be given admission to the nearest Kendriya Vidyalaya or in a private school as a day scholar.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]